MXPA02011016A - Glicopeptidos recombinantes de glucolisacion in vitro. - Google Patents

Glicopeptidos recombinantes de glucolisacion in vitro.

Info

Publication number
MXPA02011016A
MXPA02011016A MXPA02011016A MXPA02011016A MXPA02011016A MX PA02011016 A MXPA02011016 A MX PA02011016A MX PA02011016 A MXPA02011016 A MX PA02011016A MX PA02011016 A MXPA02011016 A MX PA02011016A MX PA02011016 A MXPA02011016 A MX PA02011016A
Authority
MX
Mexico
Prior art keywords
glycopeptides
vitro
provides methods
recombinantly produced
modifying
Prior art date
Application number
MXPA02011016A
Other languages
English (en)
Inventor
Robert J Bayer
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26898956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02011016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of MXPA02011016A publication Critical patent/MXPA02011016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Abstract

La presente invencion proporciona metodos para modificar los patrones de glucosilacion de los glicopeptidos, incluyendo los glicopeptidos producidos de manera recombinante. Tambien se proporcionan composiciones de glicopeptidos en las cuales los glicopeptidos tienen un patron de glucosilacion uniforme.
MXPA02011016A 2000-05-12 2001-05-14 Glicopeptidos recombinantes de glucolisacion in vitro. MXPA02011016A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20385100P 2000-05-12 2000-05-12
US09/855,320 US20020019342A1 (en) 2000-05-12 2001-05-14 In vitro modification of glycosylation patterns of recombinant glycopeptides
PCT/US2001/015693 WO2001088117A2 (en) 2000-05-12 2001-05-14 In vitro fucosylation recombinant glycopeptides

Publications (1)

Publication Number Publication Date
MXPA02011016A true MXPA02011016A (es) 2004-03-16

Family

ID=26898956

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011016A MXPA02011016A (es) 2000-05-12 2001-05-14 Glicopeptidos recombinantes de glucolisacion in vitro.

Country Status (9)

Country Link
US (5) US20020019342A1 (es)
EP (1) EP1285072A2 (es)
JP (1) JP2004528001A (es)
AU (1) AU2001263149A1 (es)
CA (1) CA2407707A1 (es)
HU (1) HUP0302299A2 (es)
MX (1) MXPA02011016A (es)
NZ (1) NZ522320A (es)
WO (1) WO2001088117A2 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693296C (en) * 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
PT1137789E (pt) 1998-12-09 2010-10-21 Phyton Holdings Llc Um método para produzir glicoproteínas possuindo glicosilação de tipo humano
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ20014123A3 (cs) * 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
IL149271A0 (en) 1999-10-26 2002-11-10 Plant Res Int Bv Mammalian-type glycosylation in plants
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
WO2002057468A2 (en) 2001-01-19 2002-07-25 The Dow Chemical Company Method for secretory production of glycoprotein having human-type sugar chain using plant cell
MXPA03008001A (es) * 2001-03-06 2004-10-15 Dow Chemical Co Celula vegetal que tiene funcion de adicion de cadena de azucar tipo animal.
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PL205352B1 (pl) * 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2003046150A2 (en) * 2001-11-28 2003-06-05 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ES2258214T3 (es) * 2002-03-07 2006-08-16 Eidgenossische Technische Hochschule Zurich Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico.
KR101060361B1 (ko) 2002-03-19 2011-08-29 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서 글리칸 프로세싱의 최적화
AU2003219402B2 (en) 2002-03-19 2008-05-08 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-n-acethylglucosamine:beta-D mannoside beta (1,4)-N-acethylglucosaminy ltransferase III) expression in plants
US20040009546A1 (en) * 2002-04-22 2004-01-15 Jan Holgersson Compositions and methods for inhibiting microbial adhesion
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
PL374580A1 (en) * 2002-07-01 2005-10-31 The Kenneth S.Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
RU2366664C2 (ru) * 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
WO2004083258A2 (en) 2003-03-14 2004-09-30 Neose Technologies Inc. Branched water-soluble polymers and their conjugates
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004103275A2 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
AU2004293103C1 (en) * 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
EP1694274B1 (en) * 2003-12-03 2013-04-24 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
WO2005070138A2 (en) * 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US7326770B2 (en) * 2004-01-22 2008-02-05 Neose Technologies, Inc. H. pylori fucosyltransferases
EP1706428B1 (en) * 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
RU2006138181A (ru) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) О-связанные гликоформы полипептидов и способ их изготовления
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
KR20070085886A (ko) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
EP1835929B8 (en) 2005-01-06 2016-07-27 Novo Nordisk A/S Anti-kir combination treatments and methods
AU2006203792B2 (en) * 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
DK2311972T3 (en) 2005-05-11 2015-04-27 Eth Zuerich Recombinant N-glycosylated proteins from prokaryotic cells
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080274958A1 (en) * 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
RU2460543C2 (ru) * 2006-10-04 2012-09-10 Ново Нордиск А/С Глицерин-связанные пэгилированные сахара и гликопептиды
FI20075030A0 (fi) * 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CA2684370C (en) 2007-04-17 2017-10-17 Plant Research International B.V. Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
WO2008151258A2 (en) * 2007-06-04 2008-12-11 Neose Technologies, Inc. O-linked glycosylation using n-acetylglucosaminyl transferases
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
EP2197919B1 (en) 2007-08-27 2014-04-09 ratiopharm GmbH Liquid formulation of g-csf conjugate
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
EP3427749A1 (en) 2008-02-20 2019-01-16 GlaxoSmithKline Biologicals SA Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
EP2166085A1 (en) * 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
EA201171259A1 (ru) * 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
PT2501406T (pt) 2009-11-19 2018-02-21 Glaxosmithkline Biologicals Sa Sistema de biossíntese que produz polissacáridos imunogénicos em células procariotas
ES2657588T3 (es) 2010-05-06 2018-03-06 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
CA2828905C (en) * 2011-03-04 2021-05-04 Glytech, Inc. Method for producing sialic-acid-containing sugar chain
EP2827882B1 (en) 2012-02-21 2020-04-08 Cytonics Corporation Systems, compositions, and methods for transplantation
US9352021B2 (en) 2013-08-28 2016-05-31 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
US10889631B2 (en) 2014-11-20 2021-01-12 Cytonics Corporation Therapeutic variant alpha-2-macroglobulin compositions
IL272987B (en) 2017-09-04 2022-08-01 89Bio Ltd fgf-21 mutant peptide conjugates and uses thereof
WO2019183531A1 (en) * 2018-03-23 2019-09-26 The Brigham And Women's Hospital COMPOSITIONS AND METHODS FOR ENFORCING FUCOSYLATION OF LACTOSAMINYL GLYCANS IN HUMAN CELLS WITH αALPHA(1,3)-FUCOSYLTRANSFERASES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032519A (en) * 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5595900A (en) * 1990-02-14 1997-01-21 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5374655A (en) * 1991-06-10 1994-12-20 Alberta Research Council Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
US6319695B1 (en) * 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
DE69434749T2 (de) * 1993-03-29 2007-04-26 Kyowa Hakko Kogyo Co., Ltd. Alpha-1,3-Fucosyltransferase
US5858752A (en) * 1995-06-07 1999-01-12 The General Hospital Corporation Fucosyltransferase genes and uses thereof
US5770420A (en) * 1995-09-08 1998-06-23 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
WO1997032889A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of Michigan MURINE α(1,3)FUCOSYLTRANSFERASE Fuc-TVII, DNA ENCODING THE SAME, METHOD FOR PREPARING THE SAME, ANTIBODIES RECOGNIZING THE SAME, IMMUNOASSAYS FOR DETECTING THE SAME, PLASMIDS CONTAINING SUCH DNA, AND CELLS CONTAINING SUCH A PLASMID
WO1998031826A1 (en) * 1997-01-16 1998-07-23 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
US6399337B1 (en) * 1997-06-06 2002-06-04 The Governors Of The University Of Alberta α1,3-fucosyltransferase

Also Published As

Publication number Publication date
EP1285072A2 (en) 2003-02-26
WO2001088117A2 (en) 2001-11-22
CA2407707A1 (en) 2001-11-22
US20030003529A1 (en) 2003-01-02
WO2001088117A3 (en) 2002-05-23
US20100322940A1 (en) 2010-12-23
US20030040037A1 (en) 2003-02-27
HUP0302299A2 (hu) 2003-10-28
US20020019342A1 (en) 2002-02-14
US20030180835A1 (en) 2003-09-25
NZ522320A (en) 2007-03-30
AU2001263149A1 (en) 2001-11-26
JP2004528001A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
MXPA02011016A (es) Glicopeptidos recombinantes de glucolisacion in vitro.
WO2003045980A3 (en) Glycopeptide remodeling using amidases
EP1461445A4 (en) GLYCOPROTEIN REMODELING USING ENDOGLYCANASES
SG147286A1 (en) Manufacture of polyglumate-therapeutic agent conjugates
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
ZA200203252B (en) Process for preparing 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycina derivatives.
MY138074A (en) Somatostatin analogues
MXPA04004939A (es) 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3-alquilados y 5,5??,6,6??,7,7??,8,8??-octahidro-2,2??-binaftoles 3,3??-dialquilados y procesos para su fabricacion.
EG23299A (en) Process for preparing 1-octene.
EP1452922A4 (en) METHOD FOR FORMING A FINE PATTERN
BR0112375A (pt) Métodos de sìntese para aplidina e novos derivados antitumorais, métodos para fabrica-los e usá-los.
MXPA02002251A (es) Diagnosticos y terapeuticos para osteoporosis.
UA87433C2 (ru) Гонадотропины для стимулирования фолликулогенеза
AU1817902A (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
MY141607A (en) Lactam compound
GB2377181A (en) Bone filler material
EP1391518A4 (en) PROCESS FOR PEPTIDE MANUFACTURE
ZA200205408B (en) Process for the preparation of peptides.
EP2298354A3 (en) Remodelling and glycoconjugation of interferon-beta
EP1413927A4 (en) METHOD FOR FORMING A FINAL MOTIF
SG185137A1 (en) Biologically active peptides
MX234329B (es) Metodo para producir n-fosfonometilglicina.
AU3818001A (en) Selective n-acylation of a82846 glycopeptide analogs
CA97011S (en) Control lever for earth moving machines
EP1335922A4 (en) NOVEL 4'-DEMETHYL-4'-O-SUBSTITUE-1-DEOXYPODOPHYLLOTOXIN DERIVATIVE, GEOMETRIC ISOMER THEREOF, PROCESS FOR PREPARING THE SAME, AND ANTI-CANCER COMPOSITION COMPRISING SAID DERIVATIVE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal